Venatorx pharmaceuticals: new antibiotics to treat drug-resistant gram-negative bacteria including public health pathogens.

Active Definitive Contract Awarded Last action

Contract number
75A50123C00050
Awardee
Awarding agency
Obligated
$45,192,122

Award facts

Opportunity
Contract value 24% obligated
  • $45,192,122.00 Current, with exercised options
  • $191,938,367.00 Potential, with all options
Completion date 50% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Malvern, PA 19355, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00011 · The purpose of this administrative modification is to correct IPP reporting. $0
Funding Only Action P00009 · The purpose of this modification is to: $5,429,906
Exercise an Option P00008 · The purpose of this modification is to exercise CLIN0002/option 1, update the period of performance for CLIN0001/base through december 31, 2027, and section… $13,312,363
Exercise an Option P00007 · The purpose of this modification is to exercise CLIN0005/option 4, update articles G.3 key personnel, G.4.G contract financial report, G.8 post award evaluation… $6,128,136
Novation Agreement P00006 · The purpose of this modification is to finalize the novation agreement via this modification the united states government recognizes that all contractual… $0
Other Administrative Action P00005 · The purpose of this no-cost modification is to update article G.7 indirect cost rates based on documentation from NIH dated april 23, 2025, and article I.1… $0
Other Administrative Action P00004 · The purpose of this modification is to update articles I.1 federal acquisition regulation (far) (48 CFR chapter 1) clauses, 52.204-14 services contract… $0
Other Administrative Action P00003 · The purpose of this modification is to update article G.1 contracting officer, article G.3 key personnel, and update attachment #1 - statement of work dated… $0
Other Administrative Action P00002 · The purpose of this modification is to update article G.7 indirect cost rate $0
Other Administrative Action P00001 · No cost modification to update section G.3 key peronnel $0
Original award $20,321,717
Show all 11

About this award

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive cost-sharing contract to Basilea Pharmaceutica International Ltd, Allschwil, on September 15, 2023, for new antibiotics against drug-resistant gram-negative bacteria, including public health pathogens. The contract carries a ceiling value of $191.9 million and no set-aside was used.

Performance is in Malvern, PA 19355, USA, with an ultimate completion date of December 31, 2029. The source states no base-plus-option structure. The work targets a new class of antibiotics acting on the lipopolysaccharide transport system in gram-negative bacteria and inhibitors of DXR, an essential enzyme not addressed by current antibiotics. The record reflects an administrative modification whose stated purpose is to correct IPP reporting.

The contract traces to a BARDA Broad Agency Announcement for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. That opportunity was posted October 16, 2017, with proposals due November 2, 2017, and a pre-proposal conference on November 7-8, 2017. The opportunity lists NAICS 541711 and 541712 and PSC codes R408 and R419. The Office of the Assistant Secretary for Preparedness and Response is the named funding agency and is civilian.

Quick answers

Who was awarded contract 75A50123C00050?

75A50123C00050 was awarded to Basilea Pharmaceutica International Ltd, Allschwil by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 15, 2023.

How much is contract 75A50123C00050 worth?

The government has obligated $45,192,122 on 75A50123C00050. Its potential value, with all options, is $191,938,367.

Was contract 75A50123C00050 competed?

The extent of competition for 75A50123C00050 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award